Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Medtronic
Harvard Business School
Dow
Merck

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Litigation Details for GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED (D.N.J. 2011)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED (D.N.J. 2011)

Docket   Start Trial Date Filed 2011-03-15
Court District Court, D. New Jersey Date Terminated 2015-12-16
Cause 35:271 Patent Infringement Assigned To Susan Davis Wigenton
Jury Demand Plaintiff Referred To Steven C. Mannion
Parties F. HOFFMANN-LA ROCHE LTD.; GENENTECH, INC.; GILEAD SCIENCES, INC.; HOFFMANN-LA ROCHE INC.; NATCO PHARMA INC.; NATCO PHARMA LIMITED
Patents 5,763,483; 5,866,601; 5,952,375
Attorneys ARNOLD B. CALMANN; DIANE C. RAGOSA; ELEONORE OFOSU-ANTWI; JENNIFER C. CRITCHLEY; KATHERINE ANN ESCANLAR; LIZA M. WALSH; READE WILLIAM SELIGMANN; RUKHSANAH L. SINGH
Firms Alston & Bird LLP; Connell, Foley; Parker Ibrahim & Berg LLp
Link to Docket External link to docket
Small Molecule Drugs cited in GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED (D.N.J. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-03-15 1 infringement of United States Patent No. 5,763,483 (“the ’483 Patent”). Plaintiffs institute this action…United States Patent and Trademark Office on June 9, 1998. 29. The ‘483 Patent claims a compound…companies to submit patent information to the FDA “with respect to which a claim of patent infringement could…lists the patent information in the “Orange Book”. 34. Plaintiffs submitted patent information…certification (commonly called a “patent certification”) with respect to each listed patent. 36. The External link to document
2015-07-21 138 DECLINING TO CONSTRUE THE DISPUTED PATENT CLAIM TERMS IN U.S. PATENT NO. 5,763,483; Because their ordinary and… 16 December 2015 2:11-cv-01455 830 Patent Plaintiff District Court, D. External link to document
2011-09-30 24 States Patent and Trademark Office issued United States Patent No. 5,763,483 (“the ‘483 Patent”) on June… infringement of United States Patent No. 5,763,483 (“the ‘483 Patent”). Case 2:11-cv-01455-SDW-MCA Document…Federal Food, Drug and Cosmetic Act for U.S. Patent No. 5,763,483 (NDA No. 021087).” 40. Denied…with the application the patent number and the expiration date of any patent which claims the drug for… (I) that such patent information has not been filed, (II) that such patent has expired, External link to document
2012-12-21 67 TAMIFLU®. (See Pls.’ Facts ¶ 9.) U.S. Patent No. 5,763,483 (the “’483 patent”), titled Carbocylic Compounds… U.S. Patent No. 5,952,375 (the “’375 patent”) and U.S. patent No. 5,866,601 (the “’601 patent”) issued…related patents, the later-issued but earlier-expiring patent can be used as a reference patent to invalidate…’483 patent issued on June 9, 1998, which is before any other patent in the Oseltamivir patent family… Inc. (See id.at ¶ 11.) The ’483 patent, ’375 patent, and ’601 patent are listed in the FDA’s Approved External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Boehringer Ingelheim
Express Scripts
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.